28/02/2015 23:33:04 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
02/27/20151:34PMBWU.S. Food & Drug Administration Accepts Biologics Licensing Application for Opdivo (nivolumab) for the Treatment of Advanced ...
Opdivo has the potential to be the first Immuno-Oncology agent approved for the treatment of advanced squamous non-small cell lung cancer Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the Biologics Licensing Application (BLA... More...>>
02/26/20153:15PMBWALLY Trial Demonstrates 97% Hepatitis C Cure Rates Among Patients Coinfected with HIV After Ribavirin-Free Investigational 12...
Daclatasvir-sofosbuvir 12-week regimen resulted in: 96% hepatitis C cure rate among patients with HVC genotype 1 disease (n=80/83) 100% hepatitis C cure rate among patients with HCV genotype 2, 3 and 4 disease (n=26/26) High HCV cure rates seen with no need to alter existing HIV medication regimens Bristol-Myers Squibb... More...>>
02/26/20158:30AMBWStudy of Next-Generation Investigational HIV-1 Maturation Inhibitor Shows Positive Results in Preventing Viral Replication vi...
Bristol-Myers Squibb’s clinical candidate represents a new class of drugs potentially able to address unmet medical needs in HIV-1 patients Proof-of-concept study supports BMS-955176 as a viable compound that overcomes limitations seen in studies of earlier maturation inhibitor candidates; Phase IIb studies for BMS-955176... More...>>
02/25/20158:30AMBW48-Week Analysis of Investigational HIV-1 Attachment Inhibitor Paves Way for Phase III Trial Initiation
Phase III trial now underway for novel therapy for heavily treatment-experienced HIV-1 patients Binding directly to the HIV virus, BMS-663068 is the first investigational antiretroviral designed to prevent initial viral attachment to host CD4+ T cells and entry into host immune cells Bristol-Myers Squibb Company (NYSE:BMY... More...>>
02/24/201510:00AMBWBristol-Myers Squibb to Present at Cowen and Company Annual Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Cowen and Company 35th Annual Global Health Care Conference on Tuesday, March 3, 2015, in Boston. Michael Giordano, senior vice president, Head of Development, Oncology, will make a formal presentation about the company at 9:20 a.m. EST. Investors and the general... More...>>
02/23/20155:00PMDJNMARKET SNAPSHOT: Dow, S&P Slump; Nasdaq Marks 9-session Win Streak
By Anora Mahmudova and Barbara Kollmeyer, MarketWatch Valeant jumps on deal news; oil, euro tumble NEW YORK (MarketWatch) -- U.S. stocks ended Monday's choppy session roughly where they started it, as a late-afternoon rebound helped pare early losses. A drop in oil prices weighed on energy companies. Meanwhile, a pickup... More...>>
02/23/20153:52PMDJNMARKET SNAPSHOT: Stocks Retreat From Records As Oil Drop Hits Energy Companies
By Anora Mahmudova and Barbara Kollmeyer, MarketWatch Valeant jumps on deal news; oil, euro tumble NEW YORK (MarketWatch) -- U.S. stocks struggled to push higher on Monday as a drop in oil prices once again hit energy companies. A pickup in merger-and-acquisition activity in the pharmaceutical industry helped push health-care... More...>>
02/23/20151:39PMDJNMARKET SNAPSHOT: U.S. Stocks Give Up Records As Oil Drop Hits Energy Companies
By Anora Mahmudova and Barbara Kollmeyer, MarketWatch Valeant jumps on deal news; oil, euro tumble NEW YORK (MarketWatch) -- U.S. stocks struggled to push higher on Monday as a drop in oil prices once again hit energy companies. A pickup in merger-and-acquisition activity Monday in the pharmaceutical industry helped push... More...>>
02/23/20151:33PMDJNMARKET SNAPSHOT: U.S. Stocks Slide As Oil Drop Hits Energy Companies
By Anora Mahmudova and Barbara Kollmeyer, MarketWatch Valeant jumps on deal news; oil, euro tumble NEW YORK (MarketWatch) -- U.S. stocks were under pressure on Monday as a slide in oil prices once again hit energy companies. A pickup in merger-and-acquisition activity Monday in the pharmaceutical industry helped push health-care... More...>>
02/23/20151:29PMDJNMARKET SNAPSHOT: U.S. Stocks: Futures Dip As Oil Slide Hits Energy Companies
By Anora Mahmudova and Barbara Kollmeyer, MarketWatch Valeant and Salix in deal news; oil, euro tumbles NEW YORK (MarketWatch) -- U.S. stock futures retreated from record levels Monday as energy companies came under pressure following a slide in oil prices. Investors await a report on existing-home sales, while assessing... More...>>
02/23/20151:27PMDJNBristol-Myers to Acquire Flexus Immunotherapy Pipeline
By Tess Stynes Bristol-Myers Squibb Co. agreed to acquire privately-held biotechnology company Flexus in a deal potentially valued at up to $1.25 billion that gives Bristol access to a pipeline of investigational immunotherapy treatments. Bristol-Myers Chief Scientific Officer Francis Cuss said the acquisition of Flexus... More...>>
02/23/201510:30AMBWBristol-Myers Squibb Foundation Awards GRU Cancer Center Three-Year, $1.74M Grant to Address Lung Cancer Among Neediest Commu...
c-CARE lung cancer module seeks to improve cancer awareness, education, detection and access to care; interventions will be tested for potential expansion statewide The Bristol-Myers Squibb Foundation today announced a three-year, $1.74 million grant to the GRU Cancer Center for a pilot program to reduce the burden of... More...>>
02/23/20158:03AMPRNUSRigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Us...
Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications PR Newswire SOUTH SAN FRANCISCO, Calif. and NEW YORK, February 23, 2015 SOUTH SAN FRANCISCO, Calif. and NEW YORK, February 23, 2015 /PRNewswire/ -- Rigel... More...>>
02/23/20158:00AMBWRigel & Bristol-Myers Squibb Announce Research & Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in...
Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel’s extensive portfolio of small molecule TGF beta receptor kinase inhibitors... More...>>
02/23/20158:00AMBWBristol-Myers Squibb To Expand Its Immuno-Oncology Pipeline with Agreement to Acquire Flexus Biosciences, Inc.
Gains full rights to Flexus’ lead preclinical IDO1 inhibitor F001287 and the company’s broad IDO/TDO discovery program Enables Bristol-Myers Squibb to fully explore the potential of IDO/TDO targeted immunotherapies in combination with its immuno-oncology portfolio Bristol-Myers Squibb Company (NYSE: BMY) and Flexus... More...>>
02/19/20154:59PMDJNTwo Coca-Cola Directors to Retire Amid Board Renovation
By Tess Stynes Coca-Cola Co. said two longtime directors plan to retire, rather than seek re-election at the company's annual shareholder meeting in April, as part of a broader changing of the guard on the beverage giant's board. The Atlanta-based company said the latest board members set to to retire are James D. Robinson... More...>>
02/05/20159:30AMBWBristol-Myers Squibb to Take Part in Leerink Swann Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Leerink Swann Global Health Care Conference on Thursday, February 12, 2015, in New York. Francis Cuss, executive vice president and chief scientific officer, will answer questions about the company at 11:10 a.m. EST. Investors and the general public are invited... More...>>
01/30/20151:04PMDJNEli Lilly Sales Hit by Patent Expirations, Currency
By Michael Calia Eli Lilly and Co. said Friday foreign-exchange pressures weighed on sales in the most recent quarter as the pharmaceutical company continued to suffer the impact of patent expirations on some of its key drugs. The company, citing the stronger U.S. dollar, adjusted its outlook for the year, including reducing... More...>>
01/29/20155:19PMBWU.S. Food & Drug Administration Approves Bristol-Myers Squibb’s Evotaz™ (atazanavir & cobicistat) for the Treatment of HI...
Evotaz is the first and only protease inhibitor pharmacoenhanced by cobicistat that is supported by comparative Phase III clinical trial data Evotaz is the only protease inhibitor pharmacoenhanced by cobicistat with virologic failure rates as low as 6% [HIV-1 RNA ≥50 copies/mL at 48 weeks: 6% Evotaz arm; 4% Reyataz®(atazanavir)/ritonavir... More...>>
01/29/20158:00AMGLOBECelldex Therapeutics and Bristol Myers-Squibb Announce Initiation of Phase 1/2 Combination Study of Varlilumab and Opdivo(R) ...
HAMPTON, N.J., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) and Bristol Myers-Squibb (NYSE:BMY) today announced the initiation of a Phase 1/2 dose escalation and cohort expansion study examining the investigational combination of varlilumab, Celldex's CD27 targeting investigational immune-activating... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy150228 23:33